Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986454 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part A: Administration of BMS-986454 | EXPERIMENTAL | - |
| Part A: Placebo | PLACEBO_COMPARATOR | - |
| Part B: Administration of BMS-986454 | EXPERIMENTAL | - |
| Part B: Placebo | PLACEBO_COMPARATOR | - |
| BMS-986454 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-986454 | DRUG | Specified dose on specified days |
| Placebo | OTHER | Specified dose on specified days |
Inclusion Criteria: * Participants with Rheumatoid Arthritis must have onset after age 18. * Participants who meet 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA. * Participants must have evidence of swelling in at least 1 joint o...
Top 20 of 28 competitors
BMS-986454 is an investigational small molecule being developed by Bristol-Myers Squibb for the treatment of rheumatoid arthritis. It is currently in Phase 1 clinical development, with studies evaluating its safety, tolerability, and drug levels in healthy participants and in patients with rheumatoid arthritis.
BMS-986454 targets CD19, a protein found on the surface of B cells. By targeting CD19, the drug may modulate B-cell activity, which is relevant to autoimmune conditions like rheumatoid arthritis. This mechanism is being investigated in early-stage clinical trials.
BMS-986454 is being developed by Bristol-Myers Squibb Company, a global biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting Phase 1 clinical trials to evaluate the drug's safety and tolerability.
BMS-986454 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials are listed: one completed study in healthy participants and one ongoing study in participants with rheumatoid arthritis.
BMS-986454 has two Phase 1 clinical trials. NCT06086886, a completed study in healthy participants in the United Kingdom with 63 enrolled, and NCT07171983, a recruiting study in participants with rheumatoid arthritis in India with a target enrollment of 46. Both are randomized, double-blind, and placebo-controlled.
No alternative names for BMS-986454 have been disclosed. The drug is referred to solely by its development code, BMS-986454, in clinical trial registrations and company communications.